Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.[1][3]
Clinical data | |
---|---|
Trade names | Eybelis, Omlonti |
Other names | UR-7276, DE-117, Omidenepag isopropyl (JAN JP) |
Routes of administration | Topical eye drops |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C26H28N6O4S |
Molar mass | 520.61 g·mol−1 |
3D model (JSmol) |
|
| |
|
Omidenepag was approved for medical use in Japan in 2018,[3] and in the United States in September 2022.[2][4]
Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.[1][3]
The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.[3]
Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.[5] Omidenepag is a selective prostaglandin E2 receptor agonist.[6][7]
Omidenepag was developed by Ube Industries and Santen Pharmaceutical.[3]